NCT02546986 2025-08-08Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung CancerCelgenePhase 2 Completed100 enrolled 27 charts
NCT02494258 2025-05-22A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological DisordersCelgenePhase 2 Completed5 enrolled
NCT02343536 2020-08-28A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed LymphomaCelgenePhase 1 Completed59 enrolled
NCT02223052 2020-05-12Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCelgenePhase 1 Completed89 enrolled
NCT01478685 2019-11-12A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid TumorsCelgenePhase 1 Completed169 enrolled
NCT02269943 2018-12-12Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal CarcinomaCelgenePhase 2 Completed36 enrolled 24 charts
NCT01835587 2018-11-20Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).CelgenePhase 1/2 Completed31 enrolled 30 charts